Bibliography Magnesium QTC HCQ

Version vom 10. August 2020, 07:15 Uhr

Mg - QTc

• THIS %22mg2%2B%22+OR+magnesium+OR+mgso4+OR+hypomagnes*+OR+hypermagnes*+OR+trpm7
• AND QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG
• NOT
• PubMed: 08/05/20 PMCentral: ----
• search on moremed.org

22174173 2011. A rare electrocardiographic manifestation of a rare form of multiple electrolyte disturbances: hyperparathyroid crisis.
8209703 1994. Hepatite aguda alcoolica complicada com arritmia cardiaca. Alcool, hepatite, hipomagnesiemia, torsade de pointes, corticoterapia.
1539780 1992. Torsade de pointes and long QT syndrome following major blood transfusion.
24303973 2013. Licorice-induced severe hypokalemia with recurrent torsade de pointes.
32389016 2020. Torsade de pointes in initiating hemodialysis: a case report.
14666271 2003. Female alcoholics: electrocardiographic changes and associated metabolic and electrolytic disorders.
23060109 2012. Serum levels of magnesium in sudden cardiac deaths among people with schizophrenia: hit or miss?
21452253 2011. Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus.
25815024 2014. Methadone induced torsades de pointes and ventricular fibrillation: A case review.
22947859 2012. Multi-ion distributions in the cytoplasmic domain of inward rectifier potassium channels.
20712994 2010. Phosphatidylinositol-4,5-bisphosphate (PIP(2)) stabilizes the open pore conformation of the Kv11.1 (hERG) channel.
11566776 2001. Unitary conductance variation in Kir2.1 and in cardiac inward rectifier potassium channels.
9788926 1998. Interaction of Ba2+ with the pores of the cloned inward rectifier K+ channels Kir2.1 expressed in Xenopus oocytes.
8842207 1996. [K+] dependence of open-channel conductance in cloned inward rectifier potassium channels (IRK1, Kir2.1).
31783793 2019. Prevalence and risk factors of prolonged corrected QT interval in general Chinese population.
30157775 2018. Effect of serum electrolytes within normal ranges on QTc prolongation: a cross-sectional study in a Chinese rural general population.
30999887 2019. Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study.
27797880 2016. Ventricular fibrillation via torsade des pointes of cardiac sarcoidosis with preserved left ventricular ejection fraction.
24121811 2013. Overdrive pacing in a patient with incessant torsades de pointes.
22987900 2012. Severe primary hypothyroidism presenting with torsades de pointes.
23203174 2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.
32169926 2020. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.
2467681 1989. Electrocardiographic findings and frequency of arrhythmias in Bartter's syndrome.
26183037 2016. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
19812810 2009. A sweet tooth as the root cause of cardiac arrest.
27212965 2016. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.
29304463 2018. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
22825908 2012. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
21660912 2011. Electrolyte disorders and arrhythmogenesis.
28357022 2012. Failure to Treat Torsades de Pointes.
24428853 2014. Antibiotic-induced cardiac arrhythmias.
18690045 2007. Differences between ion binding to eag and HERG voltage sensors contribute to differential regulation of activation and deactivation gating.
32554946 2020. Magnesium Deficiency Causes Transcriptional Downregulation of Kir2.1 and Kv4.2 Channels in Cardiomyocytes Resulting in QT Interval Prolongation.
10526691 1999. Prolongation of the QT interval in children with liver failure.
9068917 1997. A practical approach to torsade de pointes.
7902224 1993. Torsade de pointes.
8269653 1993. Magnesium and the heart: antiarrhythmic therapy with magnesium.
8416758 1993. Abnormal QT intervals associated with negative T waves induced by antiarrhythmic drugs are rapidly reduced using magnesium sulfate as an antidote.
1551265 1992. Electrophysiologic and antiarrhythmic effects of magnesium in patients with inducible ventricular tachyarrhythmia.
1660796 1991. Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts.
26251626 2015. Serum magnesium concentrations in patients receiving sodium picosulfate and magnesium citrate bowel preparation: an assessment of renal function and electrocardiographic conduction.
26069818 2012. Magnesium in disease.
29849428 2017. Methadone-induced Torsades de Pointes Masquerading as Seizures.
32670733 2020. Magnesium Supplementation Shortens Hemodialysis-Associated Prolonged QT.
22114630 2011. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.
12101132 2002. The role of magnesium in the emergency department.
31911979 2019. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report.
24940425 2014. Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes.
29731714 2018. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes.
30270992 2018. Effect of Hemodialysis on Corrected QT Interval and QTc Dispersion.
22529489 2012. Phenytoin in treatment of amiodarone-induced Torsades de pointes.
19646241 2009. Prolonged QT interval in a man with anorexia nervosa.
30305584 2018. Persistent QT Prolongation in a Child with Gitelman Syndrome and SCN5A H558R Polymorphism.
20720356 2010. Premature atrial contraction induces torsades de pointes in a patient of Takotsubo cardiomyopathy with QT prolongation.
9372331 1997. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.
19377216 2008. Improvement of maximum corrected QT and corrected QT dispersion in electrocardiography after kidney transplantation.
28471572 2016. Magnesium-Responsive Polymorphic Ventricular Tachycardia Associated with Alcoholic Binge Drinking.
31221261 2019. Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals.
11583899 2001. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
2661626 1989. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?
3711493 1986. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans.
6630761 1983. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.
26802105 2016. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death.
10361868 1999. QT dispersion in patients with end-stage renal failure and during hemodialysis.
10405219 1999. Hypomagnesemia.
29021858 2017. Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia.
19944332 2009. Torsades de Pointes with QT prolongation related to donepezil use.
24653589 2013. Torsade de pointes as a reperfusion arrhythmia following intravenous thrombolytic therapy.
22394705 2012. Pseudohypoparathyroidism presenting with ventricular arrhythmia: a case report.
16533896 2006. Functional roles of charged amino acid residues on the wall of the cytoplasmic pore of Kir2.1.
12407079 2002. Ser165 in the second transmembrane region of the Kir2.1 channel determines its susceptibility to blockade by intracellular Mg2+.
9382895 1997. A conserved arginine residue in the pore region of an inward rectifier K channel (IRK1) as an external barrier for cationic blockers.
8740374 1996. Fast inactivation causes rectification of the IKr channel.
10205594 1999. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia.
11410700 2001. A case of torsade de pointes associated with hypopituitarism due to hemorrhagic fever with renal syndrome.
18821491 2008. Cardiotoxicity after massive amantadine overdose.
18570170 2008. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.
20015154 2010. Cholesterol modulates ion channels via down-regulation of phosphatidylinositol 4,5-bisphosphate.
15618275 2005. Two Kir2.1 channel populations with different sensitivities to Mg(2+) and polyamine block: a model for the cardiac strong inward rectifier K(+) channel.
12205194 2002. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome.
12411513 2002. Identification of a site involved in the block by extracellular Mg(2+) and Ba(2+) as well as permeation of K(+) in the Kir2.1 K(+) channel.
10066894 1999. Kir2.1 encodes the inward rectifier potassium channel in rat arterial smooth muscle cells.
9508824 1998. Voltage-dependent blockade of HERG channels expressed in Xenopus oocytes by external Ca2+ and Mg2+.
7884731 1994. Torsades de pointes-like polymorphic ventricular tachycardia in a dog.
29759319 2015. Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures.
10875735 2000. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential.
12110021 2002. Electrocardiogram with prolonged QT interval in Gitelman disease.
30596175 2019. Clinical and Genetic Characteristics in Patients With Gitelman Syndrome.
23755081 2013. Acquired Long QT Syndrome Manifesting with Torsades de Pointes in a Patient with Panhypopituitarism due to Radiotherapy.
25558343 2014. Ventricular arrhythmia in patients with prolonged QT interval during liver transplantation: two cases report.
24578711 2014. Channelopathies.
21977140 2010. Polymorphic ventricular tachycardia in acute myocardial infarction treated by thrombolysis: reperfusion, complication or iatrogenic sign?
25967879 2015. The relationship between repolarization parameters and serum electrolyte levels in patients with J wave syndromes.
26878253 2015. An approach to the diagnosis and management of a case presenting with recurrent hypomagnesemia secondary to the chronic use of a proton pump inhibitor.
20353903 2010. Magnesium and cardiovascular system.
30558036 2018. Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report.
29245320 2017. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
30169383 2019. Critical Consideration of Myxedema Coma in the Postoperative Setting: A Case Report.
25470888 2014. A comparison of the effects of lidocaine or magnesium sulfate on hemodynamic response and QT dispersion related with intubation in patients with hypertension.
24397608 2014. Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.
11942876 2002. Perioperative management of long QT syndrome in a child with congenital heart disease.
20128168 2009. Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes.
30220246 2019. Hypomagnesemia and hypermagnesemia.
24697004 2013. A case of recurrent arrhythmia in an acute pancreatitis patient--pathophysiological explanation using shortage of 'repolarization reserve'.
3993440 1985. The relationship between QTc changes and nutrition during weight loss after gastroplasty.
10830458 2000. Heart risk associated with weight loss in anorexia nervosa and eating disorders: electrocardiographic changes during the early phase of refeeding.
16156840 2005. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
12534434 2003. The importance of the QT interval: a review of the literature.
7572567 1995. Torsades de pointes and long QT syndromes.
17540188 2007. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
14597941 2003. Evaluation of the dofetilide risk-management program.
11773906 2002. Long QT syndrome: diagnosis and management.
2729056 1989. Effect of the infusion of magnesium sulfate during atrial pacing on ECG intervals, serum electrolytes, and blood pressure.
49775 1975. Letter: Glycerol in cerebral oedema.

31942276 2020. Mirtazapine's effect on the QT interval in medically hospitalized patients.
22470374 2011. QT Interval and QT Dispersion in Patients Undergoing Hemodialysis: Revisiting the Old Theory.
27471598 2016. Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole.
24155819 2012. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation.
25350118 2014. Lack of negatively charged residues at the external mouth of Kir2.2 channels enable the voltage-dependent block by external Mg2+.
24681627 2014. A long QT mutation substitutes cholesterol for phosphatidylinositol-4,5-bisphosphate in KCNQ1 channel regulation.
12151568 2002. Changes in the corrected QT interval and corrected QT dispersion during haemodialysis.
1409197 1992. Sotalol-induced torsade de pointes: management with magnesium infusion.
3341171 1988. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease.
3766386 1986. Efficacy of magnesium sulfate in the treatment of torsade de pointes.
3966318 1985. Torsade de pointes and magnesium deficiency.
20723644 2010. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
12767447 2003. Prenatal diagnosis and in utero treatment of torsades de pointes associated with congenital long QT syndrome.
12586278 2003. Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts.
9354415 1997. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
2296905 1990. Magnesium sulfate is the treatment for torsades de pointes if the right dose is given.
2729150 1989. Treatment of torsade de pointes with intravenous magnesium.
2650516 1989. Magnesium treatment of ventricular arrhythmias.
6695782 1984. Magnesium therapy for torsades de pointes.
6650429 1983. Hypomagnesemic torsades de pointes.
14728075 2003. Does magnesium have a role in the treatment of patients with coronary artery disease?
8358483 1993. The importance of magnesium in cardiovascular disease.
27914889 2017. Ventricular tachycardia and prolonged QT interval presenting as seizure-like activity.
24462399 2014. The use of isoproterenol and phenytoin to reverse torsade de pointes.
23896010 2013. Citalopram and levosulpiride: a dangerous drug combination for QT prolongation.
21075581 2012. Isoproterenol as an adjunct for treatment of idiopathic ventricular fibrillation storm in a pregnant woman.
20006210 2010. Termination of drug-induced torsades de pointes with overdrive pacing.
19857426 2009. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.
9928709 1999. Torsades de pointes: a case with multiple variables.
7945604 1994. Torsades de pointes induced by erythromycin and terfenadine.
2914039 1989. Magnesium sulfate termination of torsades de pointes following failure of cardioversion.
7733096 1995. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance.
18359968 2008. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis.
15119574 2004. Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients.
8438899 1993. Induction of hypomagnesemia during Amsacrine treatment.
25864370 2015. Magnesium and Dialysis: The Neglected Cation.
25828570 2015. Dialysate and serum potassium in hemodialysis.
12500237 2003. Cell-associated magnesium and QT dispersion in hemodialysis patients.
27639872 2017. Association of Serum Magnesium on Mortality in Patients Admitted to the Intensive Cardiac Care Unit.
11812408 2002. Clinical and therapeutic aspects of congenital and acquired long QT syndrome.
3499072 1987. Torsade de pointes during administration of pentamidine isethionate.
3565423 1987. Effects of low potassium or magnesium concentrations on isolated cardiac tissue.
20610973 2010. A dyshomeostasis of electrolytes and trace elements in acute stressor states: impact on the heart.
7771501 1995. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.
8475949 1993. Case report: pentamidine and polymorphic ventricular tachycardia revisited.
12832258 2003. Side effects of ziprasidone.
14704599 2004. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis.
12845389 2003. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety.
11304665 2001. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography.
11197564 2001. Prevalence and prognostic importance of hypomagnesemia and hypocalcemia in horses that have colic surgery.
21364460 2011. Magnesium--essentials for anesthesiologists.
2301766 1990. The effect of magnesium sulfate administration on cerebral and cardiac toxicity of bupivacaine in dogs.
12678199 2003. Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.
10870859 2000. Increased QT interval dispersion after hemodialysis: role of peridialytic electrolyte gradients.
2389840 1990. Magnesium treatment of torsade de pointes--a case report.
2629617 1989. Proprietes electrophysiologiques cliniques du magnesium et correlations avec son efficacite anti-arythmique dans les torsades de pointe acquises.
8599503 1996. Magnesium sulfate for conversion of supraventricular tachycardia refractory to intravenous adenosine.
2817575 1989. Magnesium sulfate & torsade de pointes.
3304038 1987. Torsades de pointes: atypical rhythm, atypical treatment.
8572407 1995. Indications du magnesium en anesthesie-reanimation.
1363741 1992. Effets arythmogenes du chlorydrate de sultopride: correlation clinique et electrophysiologique cellulaire.
2418718 1985. Torsades de pointe et hypomagnesemie.
7469224 1981. Torsades de pointes.
3152846 1988. Il solfato di magnesio nella terapia della tachicardia ventricolare a torsione di punta.
24285766 2013. Azithromycin-induced proarrhythmia and cardiovascular death.
23362038 2013. Torsades de pointes after administration of low-dose aripiprazole.
10534216 1999. Haloperidol-induced torsade de pointes.
1477438 1992. Prolonged recurrence of pentamidine-induced torsades de pointes.
7786143 1995. Mecanisme d'action des antiarythmiques de classe III.
8267505 1993. Les torsades de pointes.
1550438 1992. Effets du magnesium sur les post-depolarisations precoces et l'activite declenchee induites par le cesium sur les fibres de Purkinje de furet.
3122681 1987. Effets electrophysiologiques du sulfate de magnesium intraveineux chez l'homme.
3087320 1986. Effets anti-arythmiques du sulfate de magnesium intraveineux dans les torsades de pointes. A propos de 6 observations.
3096233 1986. Traitement des torsades de pointes par magnesium intraveineux.
28766238 2017. Magnesium isoglycyrrhizinate inhibits L-type Ca(2+) channels, Ca(2+) transients, and contractility but not hERG K(+) channels.
14692159 2003. Torsades de pointes following cardioversion: case history and literature review.
2196873 1990. Proarrhythmic actions of antiarrhythmic drugs: a review.
9782371 1998. Generating and influencing Torsades de Pointes--like polymorphic ventricular tachycardia in isolated guinea pig hearts.
19653656 2009. Ion-blocking sites of the Kir2.1 channel revealed by multiscale modeling.
22057978 2012. Inhibition of sodium current by taurine magnesium coordination compound prevents cesium chloride-induced arrhythmias.
19655100 2010. Clinical effects of cesium intake.
10958097 2000. Management of prolonged QT interval during a massive transfusion: calcium, magnesium or both?
8595691 1995. Diuretic-induced hypokalaemia inducing torsades de pointes.
9627533 1998. Torsade de pointes with sotalol overdose treated successfully with lidocaine.
19935903 2009. Inhibitory effects of dauricine on early afterdepolarizations and L-type calcium current.
11007539 2000. Block of inwardly rectifying K+ currents by extracellular Mg2+ and Ba2+ in bovine pulmonary artery endothelial cells.
20544619 2010. Multifactorial QT interval prolongation.
14766022 2004. Vitamins, supplements, herbal medicines, and arrhythmias.
10348955 1998. Acquired QT Prolongation: Mechanisms and Implications.
2085823 1990. Magnesium and cardiac arrhythmias. Reappraisal of an old substance.
12652102 2002. The influence of magnesium on the electrophysiological effects of erythromycin in the isolated Guinea pig heart.
1854660 1991. Torsades de pointes: prevention and therapy.
1854659 1991. Terminology of torsades de pointes.
9231028 1997. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium.
9302346 1997. Magnesium abolishes inadequate kinetics of frequency adaptation of the Q-aT interval in the presence of sotalol.
8001044 1994. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts.
3256422 1988. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.
29873021 2018. The Effects of Lipid Emulsion, Magnesium Sulphate and Metoprolol in Amitriptyline-Induced Cardiovascular Toxicity in Rats.
25253561 2015. Analysis of an ECG record database reveals QT interval prolongation potential of famotidine in a large Korean population.
18690034 2007. Exaggerated Mg2+ inhibition of Kir2.1 as a consequence of reduced PIP2 sensitivity in Andersen syndrome.
19433077 2009. Modulation of haloperidol induced electrophysiological alterations on cardiac action potential by various risk factors and gender difference.
8131528 1994. Magnesium sulfate potentiates several cardiovascular and metabolic actions of terbutaline.
15746441 2005. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome.
9598592 1998. Dynamic Ca2+-induced inward rectification of K+ current during the ventricular action potential.
9168780 1997. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells.
7828315 1995. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.
1914096 1991. Polymorphous ventricular tachycardia associated with acute myocardial infarction.
2917391 1989. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium.
3370776 1988. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs.
3338130 1988. Treatment of torsade de pointes with magnesium sulfate.
22846359 2012. [Magnesium metabolism and therapeutic strategy in cardiovascular disease].
15692161 2005. [Heart rate variability, arrhythmia and magnesium in hemodialysis patients].
11453949 2001. Hyperthyroidism is associated with lengthening of ventricular repolarization.
16698131 2006. Tolerable infusion rate of citrate based on clinical signs and the electrocardiogram in conscious dogs.
2416504 1985. Drug-induced torsade de pointes.
15001976 2004. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
2974361 1988. Il problema della tachicardia ventricolare a torsione di punta e della sua razionale terapia.
27022002 2016. Not your regular high: cardiac dysrhythmias caused by loperamide.

20671821 2010. Causes and management of drug-induced long QT syndrome.
22299661 2012. The effect of different dialysate magnesium concentrations on QTc dispersion in hemodialysis patients.
26869275 2016. A synergistic blocking effect of Mg(2)(+) and spermine on the inward rectifier K(+) (Kir2.1) channel pore.
25630313 2014. Importance of QT interval in clinical practice.
31637554 2019. Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.
15616901 2004. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.
32603470 2020. Acquired Long QT Syndrome after Acute Myocardial Infarction: A Rare but Potentially Fatal Entity.
25057346 2014. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.
19907690 2009. Drugs, electrolytes and tako-tsubo cardiomyopathy: triple aetiology of acquired long QT syndrome and torsades de pointes.
25706450 2015. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
20199131 2010. A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone and triazolam in a patient receiving nifedipine.
18363122 2008. Non-fatal ventricular dysrhythmias associated with severe salicylate toxicity.
22668123 2012. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.
21649448 2011. Assessing QT interval prolongation and its associated risks with antipsychotics.
2129926 1990. Torsades de Pointes.
17879860 2007. Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities.
1989768 1991. Cardiac arrest secondary to emotional stress and torsade de pointes in a patient with associated magnesium and potassium deficiency.
3257726 1988. Torsade de pointes in a patient receiving intravenous vasopressin.
19281438 2009. The relationship between blood glucose level and QTc duration in the critically ill.
16573402 2002. Cardiac arrhythmias: diagnosis and management. The tachycardias.
12917054 2003. Advances in the acute pharmacologic management of cardiac arrhythmias.
24020938 2013. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
11096483 1999. Torsades de Pointes.
26249264 2015. QT interval prolongation associated with low magnesium in chronic alcoholics.
27241860 2017. The prevalence of QT prolongation in a population of patients with substance use disorders.
22702639 2012. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
11994029 2002. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
7727055 1994. Drug-induced torsade de pointes. Incidence, management and prevention.
8129865 1993. Class III antiarrhythmics in overdose. Presenting features and management principles.
10553703 1999. Toxicity of quinolones.
7510621 1994. Torsade de pointes. Mechanisms and management.
20210367 2010. Safety considerations of fluoroquinolones in the elderly: an update.
12641485 2003. Fluoroquinolones in the elderly: safety considerations.
11740632 2001. QT-Verlangerung und Torsade de pointes-Tachykardie bei Therapie mit Maprotilin. Differenzialdiagnostische und -therapeutische Aspekte.
7588195 1995. Wide complex tachycardia.
11217540 2000. Antipsychotiques et securite cardio-vasculaire: donnees actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires.
10099907 1999. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction.
8293755 1993. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
27154527 2019. Severe Torsades de Pointes with acquired QT prolongation.
27634841 2017. Treating arrhythmias with adjunctive magnesium: identifying future research directions.
24817413 2014. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
10853872 2000. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.
18304526 2008. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
22389418 2012. In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
19351630 2009. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
10362846 1999. Effect of extracellular cations on the inward rectifying K+ channels Kir2.1 and Kir3.1/Kir3.4.
23808631 2013. Hypomagnesemia and proton-pump inhibitors.
14585064 2003. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
31092056 2019. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias.
24147515 2013. Torsades de pointes following clarithromycin treatment.
14977544 2004. Magnesium in clinical medicine.
8458600 1993. Experimental models of torsades de pointes.
3436500 1987. I sali di magnesio nel trattamento della tachicardia ventricolare.
3556945 1986. Un caso di torsione di punta da ipomagnesiemia.
3556944 1986. "Torsione di punta" da antidepressivi triciclici. Descrizione di un caso clinico.
6532886 1984. Azione antiaritmica del solfato di magnesio nella aritmia ventricolare a "torsione di punta".
15750993 2004. Rischio aritmologico in pazienti emodializzati vs soggetti normali.
22847284 2012. Electrocardiographic, cardiac enzymes, and magnesium in patients with severe acute pancreatitis.
9888262 1999. Antiarrhythmic effects of magnesium on rat papillary muscle and guinea pig ventricular myocytes.
10461849 1999. Effects of nicardipine and bupivacaine on early after depolarization in rabbit sinoatrial node cells: a possible mechanism of bupivacaine-induced arrhythmias.
21411146 2011. Methadone-induced torsades de pointes: a twist of fate.
9333595 1997. Medikamentose antiarrhythmische Therapie. Ist eine orale adjuvante Therapie mit Elektrolyten sinnvoll?
9333593 1997. Magnesiummangel und Magnesiumsubstitution. Einfluss auf ventrikulare Herzrhythmusstorungen unterschiedlicher Atiologie.
9333592 1997. Einfluss von Magnesium auf anhaltende ventrikulare Tachykardien.
9333591 1997. Klinisch-elektrophysiologische Effekte von Magnesium, insbesondere bei supraventrikularen Tachykardien.
32025785 2020. Long- und Short-QT-Syndrome : Notfalltherapie und Sekundarprophylaxe.
9821023 1998. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case.
15586745 2004. Seventy-four defibrillations for sotalol-induced torsades de pointes.
3229780 1988. Magnesium sulfate therapy in torsades de pointes.
16096514 2005. Antipsychotic drugs and QT prolongation.
28100427 2017. The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis.
19136164 2010. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.
15301901 2004. Magnesium in treatment of acute myocardial infarction.
15159030 2004. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
15193823 2004. Female preponderance in ibutilide-induced torsade de pointes.
11203051 2000. Torsades de pointes due to multihormonal deficiency induced long QT syndrome.
2365519 1990. Magnesium sulphate for torsade de pointes in a patient with congenital long QT syndrome.
3744606 1986. Limited effect of magnesium sulphate on torsades de pointes ventricular tachycardia.
28012118 2017. Risk factors for QTc-prolongation: systematic review of the evidence.
9744153 1998. Hypomagnesaemia in postoperative patients: an important contributing factor in postoperative mortality.
21496406 2011. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting.
27943168 2017. Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes.
12122531 2002. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
14689085 2003. Tetanie.
11305536 2001. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
11760927 2001. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
17212573 2006. Acquired long QT syndrome secondary to cesium chloride supplement.
15466950 2004. Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome.
3537078 1986. Magnesium and cardiac arrhythmias: nutrient or drug?
15278621 1991. Effects of lidocaine and verapamil on early afterdepolarizations in isolated rabbit sinoatrial node.
15270138 2004. Drug-induced long QT syndrome and Torsade de Pointes.
10999172 1999. Hypomagnesemia with hypokalemia in an uncontrolled diabetic patient presenting with recurrent episodes of torsades de pointes.
17987843 2007. [Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report].
9253694 1997. [Pheochromocytoma of the left retroperitoneal paraganglion associated with torsade de pointes: a case report].
26706796 2015. Sudden Cardiac Death and Disorders of the QT Interval: Anesthetic Implications and Focus on Perioperative Management.
12108503 2002. Beta-adrenergic stimulation of pig myocytes with decreased cytosolic free magnesium prolongs the action potential and enhances triggered activity.
10355707 1999. Macroscopic T wave alternans as a harbinger of sudden death.
9300294 1997. Tissue magnesium levels and the arrhythmic substrate in humans.
9363818 1997. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model.
8269292 1993. Drug therapy for torsade de pointes.
22990234 2013. Beat-to-beat corrected QT analysis detects corrected QT prolongation in 50 consecutive telemetry-monitored patients.
17031266 2006. Role of autonomic nervous activity in the antiarrhythmic effects of magnesium sulfate in a canine model of polymorphic ventricular tachyarrhythmia associated with prolonged QT interval.
10028924 1999. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
10445681 1999. Female gender is a risk factor for torsades de pointes in an in vitro animal model.
9733356 1998. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
7475058 1995. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.
7532749 1994. Effects of magnesium on polymorphic ventricular tachycardias induced by aconitine.
1697384 1990. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions.
1691383 1990. Pharmacologic response of cesium-induced ventricular tachyarrhythmias in anesthetized dogs.
10684450 1997. Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of magnesium and Lidocaine in Torsade de Pointes.
24633623 2014. Gating of the kir2.1 channel at the bundle crossing region by intracellular spermine and other cations.
27543914 2017. QTc prolongation during peripheral stem cell apheresis in healthy volunteers.
31116446 2019. Loperamide: A Readily Available but Dangerous Opioid Substitute.
7665716 1995. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
1753009 1991. Electrophysiologic mechanisms for ventricular arrhythmias in left ventricular dysfunction: electrolytes, catecholamines and drugs.

12823094 2003. Oral magnesium ion shortens prolonged QTc interval.
27492745 2017. A multidisciplinary approach to prenatal treatment of congenital long QT syndrome.
20832817 2010. Torsades: adjacent and triggering electrocardiographic events.
9005884 1997. Torsade de pointes as a complication of subarachnoid hemorrhage: a critical reappraisal.
1735792 1992. Effect of strontium on action potential repolarization in rabbit sinoatrial node cells.
28755998 2017. Loperamide-Induced Torsades de Pointes: A Case Series.
28007361 2017. A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
17976767 2008. Management of ventricular dysrhythmia secondary to trazodone overdose.
18022786 2008. Chronic methadone therapy complicated by torsades de pointes: a case report.
1491157 1992. Magnesium: clinical considerations.
9071844 1997. Combined use of astemizole and ketoconazole resulting in torsade de pointes.
11519837 2001. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration.
11253252 2000. The electrocardiographic QT interval and its prolongation in response to medications: differences between men and women.
18846329 2008. Effects of potassium aspartate and magnesium on ventricular arrhythmia in ischemia-reperfusion rabbit heart.
8523384 1995. Two new culprits in cardiovascular disease: QT dispersion and aldosterone.
14508199 2003. Dynamic QT interval analysis in uraemic patients receiving chronic haemodialysis.
1316396 1992. Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death.
15665255 2005. Magnesium deficiency in critical illness.
25073261 2013. Treatment of methadone-induced torsades de pointes with lidocaine.
19303883 2009. Role of Mg(2+) block of the inward rectifier K(+) current in cardiac repolarization reserve: A quantitative simulation.
17582433 2007. T75M-KCNJ2 mutation causing Andersen-Tawil syndrome enhances inward rectification by changing Mg2+ sensitivity.
11829056 2002. Actions of Androctonus australis and Leiurus quinquestriatus venoms in the rat isolated atria and anesthetized rats; effect of magnesium and lidocaine.
19967647 2009. Vascular calcification and QT interval in incident hemodialysis patients.
15211156 2004. Traumatic subarachnoid hemorrhage and QTc prolongation.
12755529 2003. Woman with postpartum ventricular tachycardia and hypomagnesemia.
24353019 2013. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain.
12354276 2002. Organophosphate poisoning complicated by a tachyarrhythmia and acute respiratory distress syndrome in a child.
9580612 1998. Gender difference in the cycle length-dependent QT and potassium currents in rabbits.
8355214 1993. Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers.
15358992 2004. Magnesium homeostasis and antipsychotic-induced QTc prolongation.
14513929 2003. Antipsychotic induced prolongation of QTc interval treated with magnesium.
21677914 2011. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
6471847 1984. EKG of the month. Torsades de pointes.
9140328 1997. Recurrent ventricular tachyarrhythmias associated with QT prolongation following hydrofluoric acid burns.
7837314 1995. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity.
8230644 1993. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
1749066 1991. Treatment of torsade de pointes with intravenous magnesium in idiopathic long QT syndrome.
8973383 1996. Effects of antiarrhythmic agents and Mg2+ on aconitine-induced arrhythmias.
9057687 1996. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil.
2724543 1989. Sheehan's syndrome with hypomagnesemia and polymorphous ventricular tachycardia.
7230515 1981. Etiology of QT prolongation and T wave changes in chronic alcoholism.
28294893 2016. [On Synergism of Potassium and Magnesium in Maintenance of Myocardial Function].
17495849 2007. [The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration].
1479796 1992. Atypische Form eines Long-QT-Syndroms--ein Fallbericht.
8256055 1993. [A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs].
1325665 1992. [Antiarrhythmic effects of magnesium on single ventricular myocytes].
1348867 1992. [A case of congenital long QT syndrome associated with T wave alternans].
2047605 1991. [Efficacy of isoproterenol, magnesium sulfate and verapamil for torsade de pointes].
3532248 1986. [Clinical significance of QT interval].
8105332 1993. Does antiarrhythmic magnesium therapy enhance malarial infection?
31298598 2019. QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.
7999530 1994. Antiarrhythmic effect of parenteral magnesium on ventricular tachycardia associated with long QT syndrome.
7999528 1994. Should magnesium therapy be considered for the treatment of coronary heart disease? I. A critical appraisal of current facts and hypotheses.
1296762 1992. New data on the antiarrhythmic value of parenteral magnesium treatment: magnesium and ventricular arrhythmias.
2693848 1989. Magnesium therapy of cardiac arrhythmias in critical-care medicine.
3523053 1986. Magnesium and cardiac arrhythmias.
15301336 2004. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer.
8189766 1994. Torsades de pointes ventricular tachycardia associated with overdose of astemizole.
28828702 2017. Vergiftungen mit psychotropen Substanzen.
27906148 2016. In brief: PPIs and Torsades de Pointes.
22970526 2012. Magnesium-Mangel und Arzneimittel.
15974204 2005. Bradycardia-associated torsade de pointes and the long-QT syndromes: a case report and review of the literature.
1407620 1992. Torsione di punta iatrogena indotta da tioridazina.
10783591 1999. Cisapride e rischio di complicanze cardiache.
11349326 2001. Herzrhythmusstorungen. Torsade de pointes durch Hypokaliamie.
8587608 1996. The inward rectification mechanism of the HERG cardiac potassium channel.
18648775 2008. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
17093009 2007. Sudden cardiac death in nephrology: focus on acquired long QT syndrome.
12053061 2002. QT dispersion in renal transplant recipients.
9578069 1998. Effect of hemodialysis on the dispersion of the QTc interval.
17003569 2006. Blockade of renin-angiotensin system reduces QT dispersion and improves intracellular Ca/Mg status in hemodialysis patients.
16166802 2006. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
29923812 2018. The Identification of Torsades de Pointes via CEEG: A Case Report on a Patient with Physiologically Provoked Nonepileptic Events.
23452578 2013. QTc prolongation after brain surgery.
7993632 1994. Kir2.1 inward rectifier K+ channels are regulated independently by protein kinases and ATP hydrolysis.
18652879 2008. Elementary properties of Kir2.1, a strong inwardly rectifying K(+) channel expressed by pigeon vestibular type II hair cells.
18074575 2007. [Drug-induced long QT syndrome].
16001778 2005. [Long QT syndrome].
12136628 2002. [Drug-induced arrhythmias].
8810801 1996. [Drug-induced arrhythmias].
1685194 1991. [Torsade de pointes].
7476792 1994. Torsade de pointes and elevated magnesium and calcium requirements associated with intravenous pentamidine.
32086826 2020. Chemical cardioversion of atrial flutter and fibrillation in the pediatric population with Ibutilide.
27628760 2016. Provider Response to QTc Prolongation on Standard 12-Lead EKG: Do We Notice or Do We Care?
21039642 2013. Pregnancy and short-coupled torsades de pointes.
17976094 2007. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.
16105013 2005. Effects of intravenous magnesium in a prolonged QT interval model of polymorphic ventricular tachycardia focus on transmural ventricular repolarization.
9604253 1998. Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
7681173 1993. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes.
7690949 1993. Torsades de pointes.
1376904 1992. TU alternans, long QTU, and torsade de pointes: clinical and experimental observations.
1721131 1991. Association of humps on monophasic action potentials and ST-T alternans in a patient with Romano-Ward syndrome.
1695751 1990. Magnesium therapy in ventricular arrhythmias.
25701242 2015. Hypomagnesemic down-regulation of L-type Ca(2+) channel in cardiomyocyte as an arrhythmogenic substrate in rats.
11922507 2002. Studies of magnesium in congenital long QT syndrome.
7784240 1995. Effective use of magnesium for acquired torsade de pointes in a 4-month-old infant.
17251875 2007. Pilot study to determine the hemodynamic safety and feasibility of magnesium sulfate infusion in children with severe traumatic brain injury.
24694881 2014. Acquired long QT syndrome: a focus for the general pediatrician.
15094576 2004. Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol.
8247942 1993. Torsade de pointes.
8488140 1993. Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate.
16635167 2006. Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome.
23760993 2013. QT and JT dispersion and cardiac performance in children with neonatal Bartter syndrome: a pilot study.
12837909 2003. Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports.
19002489 2009. Human Kir2.1 channel carries a transient outward potassium current with inward rectification.
9019734 1996. Heterooligomeric assembly of inward-rectifier K+ channels from subunits of different subfamilies: Kir2.1 (IRK1) and Kir4.1 (BIR10).
15918160 2005. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
12076305 2002. Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.
29380488 2018. Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis.
29882591 2018. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review.
17316157 2007. Management of dofetilide overdose in a patient with known cocaine abuse.
8643894 1996. Der klinisch-pharmakologische Fall (2).Bradykardie und ventrikulare Tachykardia vom Typ Torsade de pointes als Nebenwirkung von Vasopressin: drei Fallberichte.
7754271 1995. Magnesium in der Kardiologie.
3157959 1985. Torsades de pointes chez l'alcoolique.
3157953 1985. Traitement des torsades de pointes par le sulfate de magnesium.
12893979 2003. Why is the QT interval measurement so critical when evaluating an ECG rhythm?
16951992 2006. Effects of metal-binding properties of human Kv channel-interacting proteins on their molecular structure and binding with Kv4.2 channel.

19508229 2009. Functional roles of EF-hands in human potassium channel-interacting protein 2.2.
16901607 2006. Hypomagnesaemia causing QT interval prolongation and torsade de pointes in an alcoholic patient.
2326522 1990. Arritmia cardiaca grave secundaria a deplecion de magnesio. Torsade de pointe.
7209092 1980. Alternancia electrica de la onda T y "torsades de pointes".
23167136 2012. Le magnesium, applications en soins intensifs et en anesthesiologie.
31373450 2019. Torsade de pointe sur interaction medicamenteuse entre sotalol et ciprofloxacine.
28692217 2016. Le magnesium dans la pratique clinique quotidienne.
24024425 2013. Le QT long acquis.
2631832 1989. Eficacia terapeutica do sulfato de magnesio por via intravenosa em taquidisritmias. A proposito de quatro casos clinicos.
8497770 1993. Gefahrliche Rhythmusstorungen.
8421775 1993. Das "cardiac ballet" mit und ohne Amiodaron.
1699270 1990. Hemiparese und Torsade de pointes unter niedrigdosierter Therapie mit Sotalol.
3070741 1988. Magnesium in der Kardiologie. Grundlagen und mogliche Indikationen.
30620510 2016. [Long QT Syndrome Induced by Antidepressants].
9459289 1998. Hypomagnesemia: renal magnesium handling.
10709414 1999. Electrocardiographic case: a middle aged, seriously ill woman with an unusual ECG and wide complex tachycardia.
8266190 1993. Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea--a case report.
11811859 2001. Magnesium: its proven and potential clinical significance.
10586828 1999. Magnesium for the next millennium.
9042182 1997. Hyperphosphatemia associated with phosphorus-containing laxatives in a patient with chronic renal insufficiency.
14963284 2004. Electrocardiographic abnormalities and serum magnesium in patients with subarachnoid hemorrhage.
19418112 2009. QT interval prolongation among patients treated with angiogenesis inhibitors.
8091345 1993. Pathologie cardiovasculaire et magnesium.
2094063 1990. Effect of magnesium sulfate on ventricular refractoriness and its efficacy for torsade de pointes.
18067651 2007. Assessment of corrected QT interval in sickle-cell disease patients who undergo erythroapheresis.
20620555 2010. Torsades de pointes triggered by severe diastolic hypotension with low hematocrit in the neohepatic stage of liver transplantation: a case report.
10770105 1999. Torsade de pointes associated with encephalitis.
8701528 1996. Torsade de pointes-takykardi ved sotalolbehandling af en normokaliaemisk patient.
15287289 2004. Eclampsia and abnormal QTc.
18365152 2008. Medikamentos induzierte Verlangerung des QT-Intervalls.
11105328 2000. Der Stellenwert von Magnesium bei Herzrhythmusstorungen.
27878411 2018. Riskante Gabe von QT-Intervall-verlangernden Wirkstoffen bei alteren Patienten mit arzneimittelinduzierter Torsade de pointes.
9064959 1996. Magnesium: Aktuelle Studien--kritische Wertung--Konsequenzen.
9064958 1996. Magnesium als antiarrhythmisches Therapieprinzip bei supraventrikularen und ventrikularen Herzrhythmusstorungen.
7502575 1995. Sotalol-induzierte Torsade-de-Pointes-Tachykardien bei einem 15 Monate alten Kleinkind.
7863684 1994. Die Bedeutung von Magnesium in der Intensivmedizin.
8147050 1993. Torsade de pointes.
29926671 2018. [Anti-arrhythmic effects of taurine-magnesium coordination compound on torsades de pointes].
8404313 1993. [Classification and treatment of torsades de pointes (TdP): a report of 11 cases].
21624302 2011. [Clinical characteristics and outcome of 32 patients with long-QT syndrome accompanied with torsade de pointes].
21624301 2011. [Clinical characteristics of 52 patients with torsade de points associated with acquired QT prolongation].
17386161 2007. [The effects of calmodulin kinase II inhibitor on ventricular arrhythmias in rabbits with cardiac hypertrophy].
15932674 2005. [Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model].
8854446 1995. Acquired long QT syndrome in a child undergoing craniotomy: a case report.

Mg - HCQ

• THIS %22mg2%2B%22+OR+magnesium+OR+mgso4+OR+hypomagnes*+OR+hypermagnes*+OR+trpm7
• AND chloroquine+OR+hydroxychloroquine
• NOT
• PubMed: 08/05/20 PMCentral: ----
• search on moremed.org

22987900 2012. Severe primary hypothyroidism presenting with torsades de pointes.
23203174 2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.
26351590 2015. Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity.
14342342 1965. SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID.
32650197 2020. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
673850 1978. The inhibition of mitochondrial DNA polymerase gamma from animal cells by intercalating drugs.
14982575 2004. Massive hydroxychloroquine overdose.
6818843 1982. Weak-base induced lysosomal secretion by macrophages: an alternative trigger mechanism that is independent of complement activation.
7977698 1994. Loss of red blood cell glutathione during Mg deficiency: prevention by vitamin E, D-propranolol, and chloroquine.
8460675 1993. Modulation of cytokines and myocardial lesions by vitamin E and chloroquine in a Mg-deficient rat model.
14067478 1963. THE RESPONSE OF HYPERCALCEMIA IN SARCOIDOSIS TO CHLOROQUINE.
2960325 1987. Inhibition of calmodulin stimulation of phosphodiesterase and Ca2+, Mg2+-ATPase activities and shape change of erythrocyte ghosts by chloroquine.
2990487 1985. Inhibition of phosphatidylinositol phosphodiesterase activity in skeletal muscle by metal ions and drugs which block neuromuscular transmission.
4312459 1969. Chloroquine and synthesis of aminoacyl transfer ribonucleic acids. Conformational changes in tryptophanyl and tryptophan transfer ribonucleic acids.
2831987 1988. Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments.
4569158 1972. The inhibition in vitro of bacterial DNA polymerases and RNA polymerase by antimalarial 8-aminoquinolines and by chloroquine.
5750458 1968. Comparison of chloroquine binding to DNA, and polyadenylic and polyguanylic acids.
18538567 2008. Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
16842209 2006. Antiplatelet and antileukocyte effects of cardiovascular, immunomodulatory and chemotherapeutic drugs.
4966073 1966. Chloroquine-mediated conversion of transfer ribonucleic acid of Escherichia coli from an inactive to an active state.
15038247 2004. Treatment with antimalarials adversely affects the oxidative energy metabolism in rat liver mitochondria.
3556432 1987. Control of membrane permeability in animal cells by divalent cations.
7895830 1995. Plasmodium falciparum and Plasmodium berghei: effect of magnesium on the development of parasitemia.
3905702 1985. Effects of chloroquine on the serum complement system.
11103308 2000. Distribution of key ions of chloroquine biotransformation and cholesterol uptake in rat liver.
1359089 1992. Adsorption of paracetamol and chloroquine phosphate by some antacids.
6292443 1982. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine.
2460697 1988. Inhibition of adsorptive endocytosis and transcytosis in pulmonary microvessels.
7382912 1980. Inhibition of hepatitis B virus specific DNA polymerase by intercalating agents.
10497894 1999. The effect of binding of chlorpromazine and chloroquine to ion transporting ATPases.
5460005 1970. The effect of chloroquine on the enzymatic hydrolysis of nucleic acids.

{{bibi|TI=HCQ - QTc|S1=chloroquine+OR+hydroxychloroquine|S2=QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG|S3=|dPMID=08/05/20|dPMC=08/05/2020}

32383430 2020. Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine.
22391528 2012. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.
32354666 2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.
32331979 2020. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
32638906 2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.
30835490 2019. Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying Kir2.1 Channels on an Automated Patch-Clamp Platform.
22369270 2012. QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.
30400791 2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.
22987900 2012. Severe primary hypothyroidism presenting with torsades de pointes.
23203174 2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.
32350872 2020. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
23701202 2013. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
32299753 2020. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
32686633 2020. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
21233253 2011. Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine.
27478650 2016. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.
19710529 2009. Chloroquine blocks a mutant Kir2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico.
32347743 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
32588427 2020. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
32285930 2020. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32605683 2020. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas.
32372695 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
32356580 2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
20585026 2010. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.
31827438 2019. The Antimalarial Chloroquine Reduces the Burden of Persistent Atrial Fibrillation.
32387247 2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.
32380291 2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
32479900 2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
32407884 2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
32438018 2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
32610165 2020. Effects of hydroxychloroquine treatment on QT interval.
32622993 2020. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk.
32621881 2020. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
32302703 2020. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32363145 2020. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
24958937 2014. Ciprofloxacin-Induced Syndrome of Inappropriate Antidiuretic Hormone; Anaphylactic Shock Due to Thrombolytic Administration; Hydroxychloroquine-Induced QT-Interval Prolongation; Complex Regional Pain Syndrome After Tetanus Toxoid Injection.
32278018 2020. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.
32621997 2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?
32621996 2020. HCQ induced QT prolongation- Primum non nocere.
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
32439366 2020. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
32623082 2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
32624690 2020. Cardiovascular disease management during the coronavirus disease 2019 pandemic.
32627127 2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
32283123 2020. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
32407770 2020. COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.
32463348 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
32463308 2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
11960982 2002. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
32753328 2020. Torsades de Pointes in Coronavirus Disease 2019 Infection.
32485061 2020. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin.
32549293 2020. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.
32731139 2020. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19.
27173501 2016. Quinine and the ABCs of Long QT: A Patient's Misfortune with Arthritis, (Alcoholic) Beverages, and Cramps.
32474031 2020. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
32418181 2020. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
32494896 2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
19285083 2009. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.
23759957 2013. Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models.
32392282 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32356863 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
26818020 2016. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.
32359771 2020. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
32442941 2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.
32511528 2020. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions.
32648153 2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.
32643072 2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.
32350818 2020. Chloroquine-induced QTc prolongation in COVID-19 patients.
29290967 2017. Modelling the effects of chloroquine on KCNJ2-linked short QT syndrome.
32654931 2020. Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19.
17213921 2007. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.
32701969 2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
11320287 2001. Recurrent syncope. Drug induced long QT syndrome.
32441496 2020. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
18216262 2008. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel.
32327397 2020. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
32501367 2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.
32694915 2020. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen.
32457932 2020. Chloroquine, hydroxychloroquine and COVID-19.
32503662 2020. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
32493478 2020. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
32493468 2020. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
32736597 2020. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
32616063 2020. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
32665039 2020. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.
32395788 2020. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series.
17984356 2007. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig.
12363064 2002. The effects of antimalarial drugs on ventricular repolarization.
31907183 2020. High-Dose Chloroquine for Uncomplicated Plasmodium falciparum Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children.
32523150 2020. Potenciales efectos pro-arritmicos de la farmacoterapia contra SARS-CoV-2.
8267504 1993. Les tachycardies ventriculaires d'origine medicamenteuse.
30738635 2019. Fetal dysrhythmias.
18182162 2008. Lysosome mediated Kir2.1 breakdown directly influences inward rectifier current density.
32687645 2020. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
32267732 2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
16615675 2006. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.
30441573 2018. Computational Analysis of the Action of Chloroquine on Short QT Syndrome Variant 1 and Variant 3 in Human Ventricles.
28216048 2017. Chloroquine blocks the Kir4.1 channels by an open-pore blocking mechanism.
14729380 2004. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.
32693652 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
16352079 2002. Antimalarial drugs inhibit the acetylcholine-receptor-operated potassium current in atrial myocytes.
23409733 2013. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement.
17590456 2008. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.
3183189 1988. Protective cardiovascular effects of diazepam in experimental acute chloroquine poisoning.
32750131 2020. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
32700555 2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
23872551 2013. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.
25654185 2015. Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
32534369 2020. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
19654266 2009. Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
7629906 1995. The hazards of chloroquine self prescription in west Africa.
31776555 2020. Drug interactions with antimalarial medications in older travelers: a clinical guide.
32356857 2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
24360369 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
17646028 2007. Cardiotoxicity of antimalarial drugs.
32706953 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
32488217 2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
12494620 2002. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.
23192368 2013. Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.
21125143 2010. Arrhythmias in systemic lupus erythematosus.

PMC

21615117 2011. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.
23685953 2013. Inside job: ligand-receptor pharmacology beneath the plasma membrane.
32517786 2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
29937880 2017. QTc prolongation in Black diabetic subjects with cardiac autonomic neuropathy.
32497913 2020. A current review of COVID-19 for the cardiovascular specialist.
32624192 2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
32425199 2020. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
25006531 2014. Gold nanoparticle-spermidine complex blocks the inward rectifier potassium channel.
32737841 2020. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
32336586 2020. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
24731243 2014. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.
32247318 2020. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
32425051 2020. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.
32232419 2020. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
24597863 2014. Assessment of inhomogeneities of repolarization in patients with systemic lupus erythematosus.
16699058 2006. Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis.
22615288 2012. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.
32571633 2020. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.
32675039 2020. Hydroxychloroquine and Potential Drug Interactions in Older Adults.
32354666 2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.
32740801 2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
31463053 2019. British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication.
22364570 2012. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.
32446195 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.
32664944 2020. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.
30400791 2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.
32409561 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
32409486 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
32169926 2020. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.
28601826 2017. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.
32384171 2020. COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
26183037 2016. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
23167578 2013. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.
20642543 2010. Drug- and non-drug-associated QT interval prolongation.
19076152 2009. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study.
16869820 2007. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.
12207642 2002. The significance of QT interval in drug development.
12207637 2002. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.
11966667 2002. Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?
3741724 1986. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.
16474415 2006. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
15655517 2005. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
12839862 2003. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
12839860 2003. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
29924137 2018. Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.
32537248 2020. Mechanisms of Myocardial Injury in Coronavirus Disease 2019.
18651395 2008. Drug-induced spatial dispersion of repolarization.
32557011 2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
32671601 2020. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
26351590 2015. Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity.
32123164 2020. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
32629149 2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
27540685 2017. Styrax blocks inward and outward current of Kir2.1 channel.
26556552 2015. Cardiac ion channels.
23221912 2013. Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
32436730 2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
32434385 2020. Cardiac Arrhythmias in COVID-19 Infection.
23449547 2013. Rotors and the dynamics of cardiac fibrillation.
32228309 2020. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.
32442023 2020. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
20142454 2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
32438948 2020. Just the facts: What drugs are safe and effective for COVID-19?
32468425 2020. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
32533455 2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?
25572282 2015. Population-based study of QT interval prolongation in patients with rheumatoid arthritis.
29497521 2012. Episodic electrolyte disorders and renal failure due to a rare disease: the McKittrick-Wheelock syndrome.
26833512 2016. Sarcoidosis of the cardio-pulmonary systems.
32422406 2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
32306288 2020. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
32495226 2020. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
32268005 2020. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
32401962 2020. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
32269021 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
30962197 2019. Use of vitamin D drops leading to kidney failure in a 54-year-old man.
29957821 2018. Immunosuppressive treatment for proliferative lupus nephritis.
21328286 2011. Azithromycin for treating uncomplicated malaria.
32384908 2020. Chloroquine for COVID-19: rationale, facts, hopes.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32467423 2020. Potential mechanisms of cardiac injury and common pathways of inflammation in patients with COVID-19.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32550090 2020. Bradycardia in Patients With COVID-19: A Calm Before the Storm?
32318865 2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.
24721648 2014. Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.
32395418 2020. An Update on Current Therapeutic Drugs Treating COVID-19.
24944403 2003. Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.
32417708 2020. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."
31835542 2019. Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology.
32696429 2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
31844421 2019. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.
25749803 2015. Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia.
21468196 2010. A practical approach to genetic hypokalemia.
32369020 2020. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
8617203 1996. Complementation between kinase-defective and activation-defective TGF-beta receptors reveals a novel form of receptor cooperativity essential for signaling.
32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.
32338155 2020. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
32562486 2020. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests.
24062937 2013. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.
32347923 2020. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
32586646 2020. Electrocardiographic features of patients with COVID-19 pneumonia.
32553587 2020. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
32283298 2020. A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
32603692 2020. Current pharmacological treatments for SARS-COV-2: A narrative review.
32441761 2020. COVID-19 and QT interval prolongation: more than just drug toxicity?
26869865 2015. A systematic review of the cardiotoxicity of methadone.
32509013 2020. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria.
21736423 2011. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.
25494485 2015. Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
32350928 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
29162702 2018. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule.
32707160 2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.

32432127 2020. COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.
26798623 2015. Long QT Syndrome: An Emerging Role for Inflammation and Immunity.
30294301 2018. Vitamin D Toxicity-A Clinical Perspective.
30532765 2018. FGF10 Protects Against Renal Ischemia/Reperfusion Injury by Regulating Autophagy and Inflammatory Signaling.
32733488 2020. Potential Fast COVID-19 Containment With Trehalose.
32733448 2020. Role of Autophagy in Lung Inflammation.
32574272 2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
29632529 2018. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?
32733907 2020. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.
32426364 2020. Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.
32391371 2020. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.
32391370 2020. The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.
31481873 2019. Hydrogen Sulfide Inhibits High Glucose-Induced Neuronal Senescence by Improving Autophagic Flux via Up-regulation of SIRT1.
31427967 2019. Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism.
29184497 2017. Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features.
31636573 2019. Enhancing Autophagy Diminishes Aberrant Ca(2+) Homeostasis and Arrhythmogenesis in Aging Rabbit Hearts.
29527175 2018. Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective.
25221519 2014. Inward rectifiers and their regulation by endogenous polyamines.
32615807 2020. Sudden cardiac death in COVID-19 patients, a report of three cases.
20543968 2010. Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.
32470824 2020. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.
14594906 2003. Drug induced QT prolongation and torsades de pointes.
32387247 2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.
32387246 2020. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.
32380291 2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
32479900 2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
32470627 2020. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.
32407884 2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
32438018 2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
32244059 2020. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.
32585191 2020. COVID-19 and cardiac arrhythmias.
26025323 2015. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32695719 2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.
32534688 2020. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
32462545 2020. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.
32389720 2020. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.
32305588 2020. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
32629115 2020. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
32738307 2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
32687949 2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.
32674929 2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
32205204 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
32565195 2020. Cardiac effects and toxicity of chloroquine: a short update.
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32450198 2020. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
32194152 2020. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
32473921 2020. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
30222237 2018. Incidence and outcomes of long QTc in acute medical admissions.
24403843 2013. Antibiotics for the treatment of rheumatoid arthritis.
32738490 2020. The continued dilemma about usage of Hydroxychloroquine: Respite is in randomized control trials.
30805547 2018. Electrocardiographic disturbances in children with systemic lupus erythematosus.
32281213 2020. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
16984815 2006. Cell biology of membrane trafficking in human disease.
27803420 2016. Acquired Gitelman Syndrome in an Anti-SSA Antibody-positive Patient with a SLC12A3 Heterozygous Mutation.
20185054 2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
27957082 2014. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.
32270559 2020. Cardiac and arrhythmic complications in patients with COVID-19.
32282502 2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
7204500 1981. Fate of plasma membrane during endocytosis. III. Evidence for incomplete breakdown of immunoglobulin in lysosomes of cultured fibroblasts.
28425222 2017. Class III antiarrhythmic drugs amiodarone and dronedarone impair KIR 2.1 backward trafficking.
32397558 2020. Impact of COVID-19 on the Cardiovascular System: A Review.
29581800 2018. Impact of Drug Induced Long QT Syndrome: A Systematic Review.
26865283 2016. Safety Concerns Surrounding Quinolone Use in Children.
31656203 2019. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
32622008 2020. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
27317161 2016. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.
30515245 2018. Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.
32494896 2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
22239221 2012. Rational approaches to improving selectivity in drug design.
32514696 2020. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.
32356252 2020. COVID-19: Therapeutics and Their Toxicities.
26159649 2016. A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening.
18072176 2007. Case files of the Drexel University Medical Toxicology Fellowship: methadone-induced QTc prolongation.
29438998 2018. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
20498233 2010. A computational model of Purkinje fibre single cell electrophysiology: implications for the long QT syndrome.
10740988 2000. Antipsychotic agents and QT changes.
32642225 2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.
32363250 2020. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials.
32313885 2020. COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.
32363351 2020. Takotsubo Syndrome in the Setting of COVID-19 Infection.
32703574 2020. Multilead QT Screening Is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era.
27042693 2016. STRUCTURAL AND FUNCTIONAL BASES OF CARDIAC FIBRILLATION. DIFFERENCES AND SIMILARITIES BETWEEN ATRIA AND VENTRICLES.
32356858 2020. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
32278373 2020. Regulators split on antimalarials for COVID-19.
32272080 2020. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.
31925317 2020. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
23864039 2013. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease.
28079193 2016. ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis.
25881046 2015. Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study.
20003315 2009. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.
18613962 2008. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.
21628620 2011. Antiparasitic therapy.
10885139 1999. Malaria in American troops in the South and Southwest Pacific in World War II.
29315692 2018. Comprehensive review of cardiovascular toxicity of drugs and related agents.
25010388 2014. HMGB1 in health and disease.
32316270 2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
29443946 2018. A Comparative Study of Human Saposins.
27869117 2016. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells.
23389616 2013. Malaria biology and disease pathogenesis: insights for new treatments.
32690910 2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.
25533796 2015. Cardiorheumatology: cardiac involvement in systemic rheumatic disease.
19347024 2009. Diagnosis and management of the neurological complications of falciparum malaria.
32430617 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
32671650 2020. SARS-CoV-2/COVID-19: a primer for cardiologists.
29434902 2018. Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide.
23760395 2013. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling.
23759954 2013. Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo.
32550240 2020. Azithromycin Should Not Be Used to Treat COVID-19.
19030406 2007. A primer of paediatric toxic syndromes or 'toxidromes'
C7378994 2020. Azithromycin/hydroxychloroquine: Lengthening of the QT interval bradycardia and atrioventricular block following an off-label use: case report.
C7404419 ä. Communication missteps during COVID‐19 hurt those already most at risk.
C7334118 2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.
C7334107 2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.
C7303435 2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.
C7290135 2020. QT interval prolongation with hydroxychloroquine plus azithromycin.
C7290151 2020. Risks of chloroquine or hydroxychloroquine use for COVID-19.
C7280102 ä. Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle.
C7300994 2020. Meeting the Challenge: Keen oversight and flexible operations keep manufacturers viable and productive despite daunting business conditions.
C7272317 2020. Hydroxychloroquine- and azithromycin-related heart disorders.
C7256915 2020. Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic.
C7257351 ä. Surface Treatments to Enhance the Functionality of PPEs.
C7212241 2020. Hydroxychloroquine-associated QT interval prolongation.
C7197234 2020. Safety concerns with higher dosage chloroquine in COVID-19 patients.
C7197245 2020. Antimalarial use in COVID-19 patients requires close monitoring.
C7262183 2020. NAATP on telemedicine and a ‘disease of isolation’.
C7148702 2016. Tourism economics and policy analysis: Contributions and legacy of the Sustainable Tourism Cooperative Research Centre.
22737589 2011. Fungal genome resources at NCBI.
29308119 2013. CONTROLLED DELIVERY OF ANTIANGIOGENIC DRUG TO HUMAN EYE TISSUE USING A MEMS DEVICE.
21630127 2011. AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development.
16353918 2005. Population pharmacokinetics/pharmacodynamics of anesthetics.
14621961 2003. Passive and iontophoretic transport enhancement of insulin through porcine epidermis by depilatories: Permeability and fourier transform infrared spectroscopy studies.
C7124145 ä. Hospital Systems Management.
25308141 2014. Using Publication Metrics to Highlight Academic Productivity and Research Impact.
22435868 2012. Optimizing Clinical Operations as part of a Global Emergency Medicine Initiative in Kumasi Ghana: Application of Lean Manufacturing Principals to Low Resource Health Systems.
20370740 2010. Improving Child Protection in the Emergency Department: A Systematic Review of Professional Interventions for Health Care Providers.
27779508 2016. “Staying in the Game”: How Procedural Variation Shapes Competence Judgments in Surgical Education.
26505105 2015. Thresholds of Principle and Preference: Exploring Procedural Variation in Postgraduate Surgical Education.
25250744 2014. What’s Behind the Scenes? Exploring the Unspoken Dimensions of Complex and Challenging Surgical Situations.
23969352 2013. Understanding Clinical Uncertainty: What Is Going on When Experienced Surgeons Are Not Sure What to Do?
32010761 2020. Academic E-Mail Overload and the Burden of “Academic Spam”.
20074982 2010. Comparison between population average and experimentally measured Arterial Input Function in predicting biopsy results in prostate cancer.
19515584 2009. Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI.
32022555 2020. Single Atom Dynamics in Chemical Reactions.
21545881 2011. The influence of novel compliant floors on balance control in elderly women—A biomechanical study.
19353388 2009. Supervisor-Student Relations: Examining the Spectrum of Conflicts of Interest in Bioscience Laboratories.
16467894 2005. Databases of Discovery.
14594412 2003. Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age.
29637764 2018. Surface-Anchored Metal–Organic Framework–Cotton Material for Tunable Antibacterial Copper Delivery.
31534827 2019. Effect of Ionic Liquid Modification on the ORR Performance and Degradation Mechanism of Trimetallic PtNiMo/C Catalysts.
30221028 2018. Tuning the Electrocatalytic Performance of Ionic Liquid Modified Pt Catalysts for the Oxygen Reduction Reaction via Cationic Chain Engineering.
32123740 2020. Synthesis of Phospho-Amino Acid Analogues as Tissue Adhesive Cement Additives.
29632885 2018. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis.
28386601 2017. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death.
25333917 2014. Reconstruction of cladoniamide biosynthesis reveals non-enzymatic routes to bisindole diversity.
22217014 2012. Inhibitors of Aminoglycoside Resistance Activated in Cells.
19278238 2009. Small Molecule Microarrays of RNA-Focused Peptoids Identifies Inhibitors of a Pathogenic Group I Intron RNA.
25695130 2015. A New Method To Image Heme-Fe Total Fe and Aggregated Protein Levels after Intracerebral Hemorrhage.
C7408243 2020. Ionic Liquid (1-Ethyl-3-methylimidazolium Acetate) Plasticization of Chitosan-Based Bionanocomposites.
32743155 2020. Waste-Printed Circuit Board Recycling: Focusing on Preparing Polymer Composites and Geopolymers.
32337441 2020. One-Pot Efficient Catalytic Oxidation for Bio-Vanillin Preparation and Carbon Isotope Analysis.
30613821 2018. Poly(glycerol sebacate)-Based Polyester–Polyether Copolymers and Their Semi-Interpenetrated Networks with Thermoplastic Poly(ester–ether) Elastomers: Preparation and Properties.
30411057 2018. iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with 68Ga and 64Cu: Unexpected Findings.
30087946 2018. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY.
30023576 2017. Fluorescent and Photosensitizing Conjugates of Cell-Penetrating Peptide TAT(47-57): Design Microwave-Assisted Synthesis at 60 °C and Properties.
31457741 2017. Giant Enhancement of Carrier Mobility in Bimetallic Coordination Polymers.
31457533 2017. Low-Cost and High-Performance Hard Carbon Anode Materials for Sodium-Ion Batteries.
31457130 2016. Field-Induced Relaxation of Magnetization in a Three-Dimensional LnMOF with the Second Bridging Ligand Squarate.
29142789 2017. Catalytic Depolymerization of Lignin and Woody Biomass in Supercritical Ethanol: Influence of Reaction Temperature and Feedstock.
25548949 2015. EXPANSION OF BISINDOLE BIOSYNTHETIC PATHWAYS BY COMBINATORIAL CONSTRUCTION.
23656278 2012. Dimerization-Dependent Green and Yellow Fluorescent Proteins.
25328143 2015. Osteopontin is associated with inflammation and mortality in a mouse model of polymicrobial sepsis.
24773521 2014. Fatal injury caused by low-energy trauma – a 10-year rural cohort.
23284336 2012. Poly[aqua­(μ2-pyrimidine-2-carboxyl­ato-κ4O N:O′ N′)(nitrato-κO)cadmium].
16511268 2006. Crystallization and preliminary X-ray diffraction analysis of a cold-adapted catalase from Vibrio salmonicida.
16508111 2005. Cloning preparation and preliminary crystallographic studies of penicillin V acylase autoproteolytic processing mutants.
18262230 2008. Hyalin is a Cell Adhesion Molecule Involved in Mediating Archenteron - Blastocoel Roof Attachment.
27708482 2016. Scientometric Dilemma: Is H-index Adequate for Scientific Validity of Academic’s Work?
25684846 2014. Factors Affecting Journal Quality Indicator in Scopus (SCImago Journal Rank) in Obstetrics and Gynecology Journals: a Longitudinal Study (1999-2013).
24825929 2014. Review of the Journal Acta Informatica Medica in 2013.
23572852 2013. Acta Informatica Medica Is Indexed In Pubmed And Archived In Pubmed Central.
23322957 2012. ON-LINE BIOMEDICAL DATABASES–THE BEST SOURCE FOR QUICK SEARCH OF THE SCIENTIFIC INFORMATION IN THE BIOMEDICINE.
27199537 2015. Imaging alterations in skeletal muscle channelopathies: a study in 15 patients.
22106717 2011. A novel N440K sodium channel mutation causes myotonia with exercise-induced weakness - exclusion of CLCN1 exon deletion/duplication by MLPA.
21314017 2010. State of the art in hereditary muscle channelopathies .
22029103 2010. Mendelian bases of myopathies cardiomyopathies and neuromyopathies.
29330575 2018. A new technique for minimal invasive complete spinal cord injury in minipigs.
26025657 2015. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy.
22526019 2012. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
27461056 2016. Impact of increased risk for fetal aneuploidy on maternal mood: a prospective longitudinal study.
30669911 2019. Clinical significance of cervical MRI in brachial plexus birth injury.
22553905 2012. Correlation between radiographic measures of acetabular morphology with 3D femoral head coverage in patients with acetabular retroversion.
20450421 2010. Correction of axial and rotational alignment after medial and lateral releases during balanced gap TKA: A clinical study of 54 patients.
18283583 2008. Cellular matrix and growth factor components of the joint capsule are modified early in the process of posttraumatic contracture formation in a rabbit model.
24644412 2014. EDITORIAL.
24453635 2013. EDITORIAL.
C7252145 ä. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.
32528832 2020. Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.
26579386 2014. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound baicalin.
20644551 2010. Ferulic acid inhibits nitric oxide-induced apoptosis by enhancing GABAB1 receptor expression in transient focal cerebral ischemia in rats.
23033877 2013. Organization of the neural switching circuitry underlying reflex micturition.
26590876 2016. Pilot randomised trial of a brief intervention for comorbid substance misuse in psychiatric in‐patient settings.
25891484 2015. Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex.
23350770 2013. Childhood catatonia autism and psychosis past and present: is there an ‘iron triangle’?
22150101 2012. Making childhood catatonia visible separate from competing diagnoses.
17244171 2007. Melancholia: restoration in psychiatric classification recommended.
12956826 2003. Postmaturity in a genetic subtype of schizophrenia.
9395159 1997. A comprehensive method of assessing routine CT scans in schizophrenia.
17280565 2007. The doctrine of the two depressions in historical perspective.
30666066 2018. The First Fifty Years of Acta Stomatologica Croatica (1966 - 2016): Citation Analysis.
30804605 2017. ACTIVITY WORKFLOW IN THE PROCESS OF ARTICLE PUBLICATION AND QUALITY CONTROL IN THE JOURNAL ACTA STOMATOLOGICA CROATICA.
27789906 2016. Acta stomatologica Croatica and PubMed Central.
18471796 2008. High Prevalence of Entamoeba moshkovskii in a Tanzanian HIV population.
29109130 2017. Effects of electroacupuncture at BL33 on detrusor smooth muscle activity in a rat model of urinary retention.
31723931 2019. Acute and Critical Care will be indexed in PubMed PubMed Central Emerging Sources Citation Index and Scopus.
26774820 2016. Negative urgency mediates the relationship between childhood maltreatment and problems with alcohol and cannabis in late adolescence.
25452074 2015. Development and psychometric properties of the Social Smoking Situations (S3) Scale: An enhanced measure of social exposure to smoking during adolescence.
24290209 2014. The effects of acute exercise on tobacco cravings and withdrawal symptoms in temporary abstinent pregnant smokers☆.
24183303 2014. Moderators of the Association Between Peer and Target Adolescent Substance Use.
18760878 2008. Nicotine dependence symptoms among young never-smokers exposed to secondhand tobacco smoke.
28429843 2018. Pooled analysis of three randomized double-blind placebo controlled trials with rimonabant for smoking cessation.
28317210 2017. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: A respondent-driven sampling study.
24467265 2014. Association among different measures of alcohol use across adolescence and emerging adulthood.
24304295 2014. TESTING A SOCIAL ECOLOGICAL MODEL OF ALCOHOL USE: THE CALIFORNIA 50 CITY STUDY.
22296280 2012. Preferences for Evidence–Based Practice Dissemination in Addiction Agencies Serving Women: A Discrete–Choice Conjoint Experiment.
24977037 2012. Past Fame Present Frames and Future Flagship? An Exploration of How Health is Positioned in Canadian Foreign Policy.
23087490 2011. On the Nature and Strategies of Organized Interests in Health Care Policy Making.
28111591 2015. Delinquent behaviors among students exposed to family violence in Quebec schools.
28111592 2015. Health Outcomes of Sexual-Minority Youth in Canada: An Overview.
29177764 2018. ROCK and RHO Playlist for Preimplantation Development: Streaming to HIPPO Pathway and Apicobasal Polarity in the First Cell Differentiation.
23227044 2012. Do Peers See More in a Paper Than Its Authors?
20936175 2010. Designing Efficient Spaced Seeds for SOLiD Read Mapping.
20150956 2009. Synonymous Codon Usage Analysis of Thirty Two Mycobacteriophage Genomes.
26601093 2015. Potential risk factors associated with stress urinary incontinence among Iranian women.
24560216 2014. Comparison between the behavior of different hydrophobic peptides allowing membrane anchoring of proteins.
19233238 2009. Antioxidant Enzyme Gene Transfer for Ischemic Diseases.
28865027 2017. Drebrin and Spermatogenesis.
26002737 2015. Use of Chemical Auxiliaries to Control P450 Enzymes for Predictable Oxidations at Unactivated C–H Bonds of Substrates.
23955676 2014. Iatrogenic genetic damage of spermatozoa.
20384219 2010. Artificial Cell Microencapsulated Stem Cells in Regenerative Medicine Tissue Engineering and Cell Therapy.
29755309 2017. Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.
18688288 2007. Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2.
28116565 2017. Pulling together and pulling apart: influences of convergence and divergence on distributed healthcare teams.
21318045 2011. Recent Advances in the Pathobiology of Hodgkin s Lymphoma: Potential Impact on Diagnostic Predictive and Therapeutic Strategies.
31172125 2019. Demography of Medical Journals in Iran; a Cross-Sectional Study.
32551324 2020. Effectiveness in Bowel Cleansing and Patient Tolerability of Polyethylene Glycol versus Sodium Picosulphate in Patients Undergoing Colonoscopy.
31886452 2018. The Psychological Science Accelerator: Advancing Psychology through a Distributed Collaborative Network.
30775689 2018. Writing Empirical Articles: Transparency Reproducibility Clarity and Memorability.
30971863 2018. Multi-domain Causal Structure Learning in Linear Systems.
18486688 2008. Strain Theory of Malaria: The First 50 Years.
21907908 2011. Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors.
21081213 2010. The Cardiovascular Physiology and Pharmacology of Endothelin-1.
31637168 2019. Single Molecule Magnetism with Strong Magnetic Anisotropy and Enhanced Dy∙∙∙Dy Coupling in Three Isomers of Dy‐Oxide Clusterfullerene Dy2O@C82.
29938193 2018. A Nacre‐Like Carbon Nanotube Sheet for High Performance Li‐Polysulfide Batteries with High Sulfur Loading.
31192867 2019. Use of Thermal Imaging to Identify Deep-Tissue Pressure Injury on Admission Reduces Clinical and Financial Burdens of Hospital-Acquired Pressure Injuries.
22400020 2012. Neurogenic Bladder.
24761357 2014. Clinical Trials Involving Biphasic Pulsed Current MicroCurrent and/or Low-Intensity Direct Current.
C7148074 ä. Ranking Significant Discrepancies in Clinical Reports.
C7148057 ä. DSR: A Collection for the Evaluation of Graded Disease-Symptom Relations.
22238503 2011. Satellite Remote Sensing for Developing Time and Space Resolved Estimates of Ambient Particulate in Cleveland OH.

24309315 2011. Ionic channels as targets for drug design: a review on computational methods.
18693297 2008. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
29921647 2018. Mechanisms and Drug Development in Atrial Fibrillation.
21079043 2010. Drug-induced long QT syndrome.
28720428 2017. Inhibitors of connexin and pannexin channels as potential therapeutics.
22274552 2012. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.
26660852 2016. KATP Channels in the Cardiovascular System.
32134952 2020. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data.
25093754 2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
22087077 2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
30517121 2018. Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus.
27064990 2016. Relationship between QT Interval Length and Arterial Stiffness in Systemic Lupus Erythematosus (SLE): A Cross-Sectional Case-Control Study.
26296197 2015. Probucol-Induced alpha-Tocopherol Deficiency Protects Mice against Malaria Infection.
25793535 2015. Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.
24205103 2013. AfroDb: a select highly potent and diverse natural product library from African medicinal plants.
22493697 2012. Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion.
19771169 2009. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
27467575 2016. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
26086192 2015. Targeting Human Transmission Biology for Malaria Elimination.
15811881 2005. Acute poisoning: understanding 90% of cases in a nutshell.
11009581 2000. QT prolongation due to roxithromycin.
432163 1979. Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.
19287558 2008. Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature.
10984545 2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
32425246 2020. Psychopharmacology of COVID-19.
31878817 2020. Acquired long QT syndrome in chronic kidney disease patients.
32409150 2020. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
32394513 2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
30858628 2019. Cardiac and vascular complications in rheumatoid arthritis.
30042604 2018. Antimalarials - are they effective and safe in rheumatic diseases?
32536565 2020. Living evidence in response to controversies about the use of antimalarials in COVID-19.
32493574 2020. COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity.
32638884 2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
31953740 2020. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.
22953235 2012. Emerging zoonoses: the "one health approach".
30532635 2018. Prevalence of Torsades de Pointes inducing drugs usage among elderly outpatients in North Jordan Hospitals.
19563673 2009. Management of the critically poisoned patient.
24981420 2014. Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells.
23953801 2013. Extracellular potassium homeostasis: insights from hypokalemic periodic paralysis.
25630313 2014. Importance of QT interval in clinical practice.
32528194 2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
7787469 1995. Use of amiodarone in the postmyocardial infarction patient.
25083239 2012. Drug-induced QT interval prolongation: mechanisms and clinical management.
25165550 2013. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.
25165548 2013. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.
29201344 2017. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.
32368072 2020. Refractory Sarcoidosis: A Review.
30867824 2019. Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
32418730 2020. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
32387694 2020. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
32387409 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
32289548 2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
32593867 2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
30794895 2019. Drug repurposing for new, efficient, broad spectrum antivirals.
32726238 2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
23675554 2013. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management.